• 1. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130
• 2. Estimation of activation energy for electroporation and pore growth rate in liquid crystalline and gel phases of lipid bilayers using molecular dynamics simulations?
  Amit Kumar Majhi,Subbarao Kanchi,V. Venkataraman,K. G. Ayappa,Prabal K. Maiti Soft Matter, 2015,11, 8632-8640
• 3. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
• 4. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 5. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615

Recent Advances in the Application of 4-Chloromethyl-5-fluoro-2-iodopyridine (CAS: 1807267-17-9) in Chemical Biology and Pharmaceutical Research

The compound 4-Chloromethyl-5-fluoro-2-iodopyridine (CAS: 1807267-17-9) has recently emerged as a versatile building block in medicinal chemistry and chemical biology research. This halogen-rich heterocyclic scaffold has attracted significant attention due to its unique reactivity profile, which enables diverse functionalization strategies for drug discovery and bioconjugation applications. Recent studies have demonstrated its utility in the synthesis of targeted covalent inhibitors, PET radiotracers, and bioactive small molecule probes.

In a 2023 study published in the Journal of Medicinal Chemistry, researchers utilized 4-Chloromethyl-5-fluoro-2-iodopyridine as a key intermediate for developing irreversible kinase inhibitors targeting EGFR mutants. The chloromethyl group served as an effective electrophile for covalent bond formation with cysteine residues, while the iodo substituent enabled subsequent Suzuki-Miyaura cross-coupling reactions to introduce various pharmacophores. This dual functionality significantly expanded the structure-activity relationship exploration for this inhibitor class.

Another important application was reported in ACS Chemical Biology, where the compound was employed as a radioiodination precursor for developing novel positron emission tomography (PET) probes. The 5-fluoro substitution provided metabolic stability, while the 2-iodo position allowed for straightforward isotopic exchange with [124I] for imaging applications. This approach demonstrated superior in vivo stability compared to traditional radioiodination methods, with potential applications in oncology and neuroscience research.

Recent synthetic methodology developments have also expanded the utility of this scaffold. A 2024 Nature Protocols publication detailed optimized conditions for regioselective functionalization at each reactive site (chloromethyl, fluoro, and iodo positions), enabling parallel synthesis of diverse compound libraries. This protocol has been particularly valuable for fragment-based drug discovery programs targeting protein-protein interactions.

From a safety and handling perspective, new stability data published in Organic Process Research & Development (2023) have provided important insights into the storage and handling requirements of 4-Chloromethyl-5-fluoro-2-iodopyridine. The studies recommend anhydrous conditions at -20°C for long-term storage, with particular attention to preventing light-induced decomposition of the iodo functionality.

Looking forward, several research groups have reported preliminary results using this scaffold for targeted protein degradation (PROTACs) and covalent fragment-based screening. The unique combination of reactive handles makes it particularly suitable for these emerging drug discovery paradigms. Ongoing clinical trials of compounds derived from this scaffold are expected to report results in 2025, which may further validate its pharmaceutical relevance.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)